Merck receives positive EU CHMP opinion for pembrolizumab plus Trastuzumab and Chemotherapy as first-line treatment for HER2-positive advanced gastric or gastroesophageal junction

If approved, KEYTRUDA would be the first immunotherapy for the first-line treatment of HER2-positive advanced gastric or GEJ cancer in tumors expressing PD-L1 (CPS ?1) in the EU

Industry needs to establish a self-regulatory body to maintain the quality of the pharma products, says Dr Mandaviya

Pembrolizumab + Trastuzumab and chemotherapy met primary endpoint as first line of treatment for GEJ

Based on a subgroup analysis by PD-L1 expression from KEYNOTE-811, Merck is working with the US FDA to update the current indication for KEYTRUDA in HER2-positive gastric or GEJ adenocarcinoma

Keytruda+ chemotherapy improves overall survival versus chemotherapy alone for unresectable advanced pleural mesothelioma

In Phase 3 CCTG IND.227/KEYNOTE-483 trial, KEYTRUDA plus chemotherapy also demonstrated statistically significant improvements in PFS and ORR compared to chemotherapy alone

Mandaviya to inaugurate conference on 'India Pharma & India Medical Devices’ on May 26-27

8th Edition of the event to promote India as a manufacturing hub of quality medical products in the Pharmaceutical and Medical Devices Sector

Moderna and Merck announce an investigational individualized neoantigen therapy

mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients

FDA accepts application for Merck’s Keytruda plus chemotherapy as first-line treatment for metastatic gastric

Acceptance based on results from the Phase 3 KEYNOTE-859 trial, which showed significant overall survival benefit in these patients with HER2-negative disease, regardless of PD-L1 expression

mRNA-4157/V940in combination with Keytruda receives PRIME scheme designation from EMA

Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial and unmet need for additional therapeutic options for certain types of melanoma

Keytruda + chemotherapy improved overall survival versus chemotherapy alone as for advanced malignant pleural mesothelioma

For the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma

Biliary tract cancer drug Durvalumab approval key opportunity for AstraZeneca in India, says GlobalData

The British-Swedish pharma major certainly has a strong competitive edge for BTC treatment in the country